Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity

Many mechanisms have been proposed for how heightened aerobic glycolytic metabolism fuels cancer pathogenicity, but there are still many unexplored pathways. Here, we have performed metabolomic profiling to map glucose incorporation into metabolic pathways upon transformation of mammary epithelial cells by 11 commonly mutated human oncogenes. We show that transformation of mammary epithelial cells by oncogenic stimuli commonly shunts glucose-derived carbons into synthesis of sialic acid, a hexosamine pathway metabolite that is converted to CMP-sialic acid by cytidine monophosphate N-acetylneuraminic acid synthase (CMAS) as a precursor to glycoprotein and glycolipid sialylation. We show that CMAS knockdown leads to elevations in intracellular sialic acid levels, a depletion of cellular sialylation, and alterations in the expression of many cancer-relevant genes to impair breast cancer pathogenicity. Our study reveals the heretofore unrecognized role of sialic acid metabolism and protein sialylation in regulating the expression of genes that maintain breast cancer pathogenicity.

[1]  Paul A Clemons,et al.  Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. , 2015, Cancer discovery.

[2]  D. Sabatini,et al.  Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.

[3]  M. Sperandio The expanding role of α2‐3 sialylation for leukocyte trafficking in vivo , 2012, Annals of the New York Academy of Sciences.

[4]  G. Adema,et al.  Sialic acids sweeten a tumor's life. , 2014, Cancer research.

[5]  M. Sola-Penna,et al.  Epithelial Mesenchymal Transition Induces Aberrant Glycosylation through Hexosamine Biosynthetic Pathway Activation* , 2016, The Journal of Biological Chemistry.

[6]  P. Dhawan,et al.  Role of CXCL1 in tumorigenesis of melanoma , 2002, Journal of leukocyte biology.

[7]  E. Papadimitriou,et al.  Cell surface nucleolin as a target for anti-cancer therapies. , 2014, Recent patents on anti-cancer drug discovery.

[8]  F. Balkwill Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[9]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[10]  Melinda M. Mulvihill,et al.  Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. , 2015, ACS chemical biology.

[11]  P. Dawson,et al.  Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA‐N‐5 neuroblastoma cells , 2000, Journal of neuroscience research.

[12]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[13]  K. Fisher,et al.  Mapping Proteome-Wide Targets of Environmental Chemicals Using Reactivity-Based Chemoproteomic Platforms. , 2015, Chemistry & biology.

[14]  S. Hofmann Palmitoyl-Protein Thioesterase , 2002 .

[15]  Kyung-Soon Park,et al.  ELK3 Expression Correlates With Cell Migration, Invasion, and Membrane Type 1-Matrix Metalloproteinase Expression in MDA-MB-231 Breast Cancer Cells. , 2015, Gene expression.

[16]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[17]  S. Jakowlew Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.

[18]  H. Coller,et al.  The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. , 2010, Genes & development.

[19]  D. Legler,et al.  Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses , 2016, Journal of leukocyte biology.

[20]  P. Yaswen,et al.  A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.

[21]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[22]  C. Bertozzi,et al.  Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation , 2007, Nature Protocols.

[23]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[24]  Jeong-Seok Nam,et al.  Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation , 2012, Cancer science.

[25]  G. Dawson,et al.  Palmitoyl Protein Thioesterase 1 Protects Against Apoptosis Mediated by Ras—Akt—Caspase Pathway in Neuroblastoma Cells , 2000, Journal of neurochemistry.

[26]  M. Bryś,et al.  O-GlcNAcylation and Metabolic Reprograming in Cancer , 2014, Front. Endocrinol..

[27]  Julia Jellusova,et al.  Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22 , 2011, Front. Immun..

[28]  R. Takimoto,et al.  RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells , 2014, Gastric Cancer.

[29]  S. Kurtzman,et al.  Interleukin-1 Family Expression in Human Breast Cancer: Interleukin-1 Receptor Antagonist , 2000, Cancer investigation.

[30]  Daniel K Nomura,et al.  Global profiling strategies for mapping dysregulated metabolic pathways in cancer. , 2012, Cell metabolism.

[31]  A. Giordano,et al.  Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model , 2015, Oncotarget.

[32]  S. Jakowlew Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.

[33]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[34]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[35]  K. Schwertfeger,et al.  Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. , 2010, Current drug targets.

[36]  P. Crocker,et al.  New Functions for the Sialic Acid‐Binding Adhesion Molecule CD22, a Member of the Growing Family of Siglecs , 2001, Scandinavian journal of immunology.

[37]  M. Hou,et al.  Inhibition of Chemokine (C-C Motif) Receptor 7 Sialylation Suppresses CCL19-Stimulated Proliferation, Invasion and Anti-Anoikis , 2014, PloS one.

[38]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .